A股異動 | 華森製藥漲停 一前列腺藥過一致性評價
格隆匯3月23日丨華森製藥(002907.SZ)漲停,報16.08元,總市值65億元。華森製藥宣佈,公司於日前收到國家藥監局核准簽發的有關《藥品補充申請批准通知書》,其申報的“鹽酸特拉唑嗪膠囊”經審查通過仿製藥質量和療效一致性評價。鹽酸特拉唑嗪膠囊主要用於治療良性前列腺增生症,該藥品是《良性前列腺增生中西醫結合診療指南(2017)》推薦用藥,被列入《國家基本藥物目錄》(2018年版)及《國家醫保藥品目錄》(2004-2021年版)。截至目前,國內已經通過或視同通過一致性評價的鹽酸特拉唑嗪膠囊企業有3家。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.